| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net (loss) income | -104,586 | -60,452 |
| Depreciation expense | 3,210 | 1,980 |
| Stockbased compensation expense | 15,251 | 10,135 |
| Amortization/(accretion) of marketable securities | 3,038 | 2,299 |
| Collaboration receivable | -2,484 | -2,500 |
| Prepaid expenses and other current assets | -6,138 | -2,407 |
| Right-of-use assets, operating leases | -8,998 | -5,439 |
| Other non-current assets | -121 | -85 |
| Accounts payable | -922 | -2,231 |
| Accrued expenses and other current liabilities | 2,592 | -1,145 |
| Income tax payable | -47 | -667 |
| Operating lease liabilities | -6,807 | -4,464 |
| Deferred revenue | -19,703 | -19,284 |
| Net cash used in operating activities | -96,309 | -67,996 |
| Purchases of property and equipment | 1,248 | 1,419 |
| Purchases of marketable securities | 123,140 | 96,574 |
| Maturities of marketable securities | 212,077 | 136,573 |
| Net cash provided by (used in) investing activities | 87,689 | 38,580 |
| Proceeds from issuance of common stock and pre-funded warrants in registered direct offering, net of issuance costs paid | 0 | 0 |
| Proceeds from exercise of stock options | 378 | 370 |
| Proceeds from issuance of common stock under the employee stock purchase plan | 317 | 317 |
| Net cash provided by financing activities | 695 | 687 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -7,925 | -28,729 |
| Cash and cash equivalents at beginning of period | 105,161 | - |
| Cash and cash equivalents at end of period | 97,236 | - |
Entrada Therapeutics, Inc. (TRDA)
Entrada Therapeutics, Inc. (TRDA)